New drug combo shows promise for Hard-to-Treat cancers
NCT ID NCT04977453
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults with certain cancers like lung, kidney, or cervical cancer are being enrolled. This is an early-phase trial, so the main focus is safety and finding the right dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
-
Carolina Biooncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
-
Chungnam National University Hospital
RECRUITINGDaejeon, Daejeon, 65015, South Korea
-
Ewha Womans University Mokdong Hospital
RECRUITINGSeoul, Yangcheon-gu, 07985, South Korea
-
Korea University Anam Hospital
RECRUITINGSeoul, Seongbuk-gu, 02841, South Korea
-
Samsung Medical Center
RECRUITINGSeoul, Gangnam, 06351, South Korea
-
Seoul National University Bundang Hospital
RECRUITINGSeoul, Bundang-gu, 13620, South Korea
-
The Catholic University of Korea Seoul ST.MARY'S Hospital
RECRUITINGSeoul, Banpo-daero, 06591, South Korea
-
The Catholic University of Korea St. Vincent's Hospital
RECRUITINGSuwon, Kyeonggi-do, 16247, South Korea
-
Tisch Cancer Institute (TCI), Icahn School of Medicine
RECRUITINGNew York, New York, 10029-5674, United States
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, 03722, South Korea
-
Yonsei University Health System, Severance Hospital
RECRUITINGSeoul, 03722, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can your own immune cells beat advanced cancer?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?